@FierceBiotech: J&J gets $116M to help hustle along new Ebola vaccine. Article | Follow @FierceBiotech
@JohnCFierce: We are slowly ramping up Asia reporting this month ahead of FiercePharmaAsia launch in Feb. Good time to start sending embargoed news my way. | Follow @JohnCFierce
@DamianFierce: $ENTA gets $50M for EU approval of $ABBV's hep C combo. From #JPM15, here's what they're going to do with it. More | Follow @DamianFierce
> At this week's JP Morgan Healthcare Conference, BioMarin ($BMRN) CEO Jean-Jacques Bienaime touted the Duchenne muscular dystrophy-treating drisapersen, acquired in its buyout of Prosensa, as superior to a rival drug from Sarepta ($SRPT), sparking a testy exchange between the two companies. Story
> Kite Pharma ($KITE), a contender in the novel space of CAR-T therapies for cancer, says its early-stage candidate could sell for $150,000 per treatment once it hits the market, undercutting analyst expectations for the class of drugs. More
> AbbVie's ($ABBV) combination hepatitis C treatment won European approval, triggering a $50 million payout for partner Enanta Pharmaceuticals ($ENTA). News
Medical Device News
@FierceMedDev: FDA, CDC investigating death, illnesses from IV bags intended for training. News | Follow @FierceMedDev
@VarunSaxena2: J&J says fishy phone calls recruiting women to file vaginal mesh-related suits warrant an investigation. More | Follow @VarunSaxena2
@EmilyWFierce: Gilead blazes ahead in hep C pricing battle with two new PBM deals. Report | Follow @EmilyWFierce
> Bill introduced in Congress to simplify marketing of research use only devices and diagnostics. Story
> Medical device, diagnostic venture investment at $2.7B, highest since 2008. More
Pharma News
@FiercePharma: Boehringer mulls sale of generic plant as stateside shakeup continues. More | Follow @FiercePharma
@CarlyHFierce: With Rytary approval in the bag, Impax Labs scouts buyouts in CNS, generics. Article | Follow @CarlyHFierce
> Gilead blazes ahead in hep C pricing battle with two new PBM deals. More
> Depomed picks up U.S. Nucynta rights as J&J's cast-off moves continue. Article